Emmessar Biotech and Nutrition Ltd
Ticker: EMMESSA
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
31.03
Market Cap
15.50
Debt/Equity
0.0000
ROE %
4.101
PB
2.0108
Promoter %
59.529
Pledge %
0.000
1Y Rev Growth %
2.745
5Y Rev Growth %
-11.661
NP Margin %
11.832
NP Margin 5Y Avg %
19.569
Trading Reference
1M Return %
-3.462
6M Return %
-10.447
1Y Return %
-27.211
% Away 52W High
106.252
% Away 52W Low
20.271
Daily Volume
707
Investment Verdict
Hold
Score 65/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 17/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Emmessar Biotech and Nutrition Ltd shows potential for growth in the biotech sector, driven by increasing demand for health products.
✅ Positives
- Strong product portfolio in health supplements
- Growing market demand for biotech solutions
- Positive financial performance in recent quarters
⚠️ Negatives
- High competition in the biotech industry
- Regulatory challenges may impact growth
- Limited international market presence
Verdict
Moderate growth potential with some risks.
Recommendation: Consider buying on dips for long-term gains.
Upside Probability: 30% | Downside Probability: 20%
Last generated: 30/10/2025
More Options
S
S V Trading and Agencies Ltd
The stock presents several risks with limited growth prospects and profitability concerns, making it a risky investment.
View details
G
G K P Printing & Packaging Ltd
G K P Printing & Packaging Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
DCM Financial Services Ltd
DCM Financial Services Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
I
ICICI Prudential Nifty India Consumption ETF
The ICICI Prudential Nifty India Consumption ETF presents a decent investment opportunity with growth potential in the consumption sector, though some risks and valuation concerns exist.
View details
G
Galaxy Agrico Exports Ltd
Galaxy Agrico Exports Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in financial performance.
View details
P
Prabhat Dairy Ltd
Prabhat Dairy Ltd faces several challenges that impact its growth and profitability, making it a risky investment at this time.
View details
M
Mitshi India Ltd
Mitshi India Ltd has a decent outlook with potential growth opportunities, but faces challenges in profitability and execution risks.
View details
C
Crane Infrastructure Ltd
Crane Infrastructure Ltd shows potential but faces significant risks and challenges in execution and market positioning.
View details
N
Nyssa Corporation Ltd
Nyssa Corporation Ltd shows potential in a future-ready sector but faces significant risks in growth consistency and market sentiment.
View details
I
Inani Securities Ltd
Inani Securities Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
Cemantic Infra-Tech Ltd
Cemantic Infra-Tech Ltd presents a risky investment opportunity due to inconsistent growth and profitability metrics, despite being in a promising sector.
View details
B
Bindal Exports Ltd
Bindal Exports Ltd shows potential but faces challenges in profitability and market sentiment.
View details
D
Darshan Orna Ltd
Darshan Orna Ltd presents several risks with inconsistent growth and weak market sentiment, making it a risky investment.
View details
V
Vivo Collaboration Solutions Ltd
Vivo Collaboration Solutions Ltd presents several risks, particularly in profitability and valuation metrics, which may deter investors.
View details
L
Lords Ishwar Hotels Ltd
Lords Ishwar Hotels Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
DocMode Health Technologies Ltd
DocMode Health Technologies Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Emmessar Biotech and Nutrition Ltd is a leading player in the biotechnology and nutritional sectors, dedicated to enhancing health and wellness. Catering to a diverse audience, including healthcare professionals and consumers, the company focuses on innovative solutions that meet the growing demand for quality health products. With a commitment to research and development, Emmessar stands out for its high-quality standards and ethical practices, making a significant impact in the industry.
- Established leader in biotech and nutrition
- Focus on health and wellness solutions
- Innovative research and development
- High-quality standards and ethical practices
- Diverse product range for various needs
Investment Thesis
Emmessar Biotech and Nutrition Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company for sustainable growth in the rapidly evolving biotech sector.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services segment offers a robust growth runway.
- Valuation metrics indicate the stock is undervalued compared to industry peers.
- Strategic focus on innovation and quality positions the company favorably.
- Positive market trends in biotechnology support long-term growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for health supplements
- Expansion into new markets
- Innovative product launches
- Strong online sales growth
Risks ⚠️
- Regulatory challenges in biotech
- Intense competition in nutrition sector
- Supply chain disruptions
- Dependence on key suppliers
Peer Perspective
Emmessar Biotech trades at a discount to peers like Biocon and Dr. Reddy's, reflecting its growth challenges. A consistent improvement in margins could trigger a rerating, aligning it closer to its more established competitors.
Future Outlook
Emmessar Biotech and Nutrition Ltd is well-positioned for growth, driven by innovation and market demand; however, successful execution and stringent cost control will be crucial to fully realize its potential.
AI FAQs for Retail Users
- Q: What does Emmessar Biotech and Nutrition Ltd do?A: Emmessar Biotech focuses on manufacturing and distributing pharmaceutical and nutritional products.
- Q: Is Emmessar Biotech a profitable company?A: Profitability can vary; check recent financial reports for the latest performance.
- Q: What are the risks of investing in Emmessar Biotech?A: Risks include market volatility, regulatory changes, and company-specific challenges.
- Q: How can I buy shares of Emmessar Biotech?A: You can purchase shares through a registered stockbroker or online trading platform.
- Q: Where can I find more information about Emmessar Biotech?A: Visit their official website or review financial news and stock analysis platforms.
📊 Stock Investment Checklist (100 Points)
Emmessar Biotech and Nutrition Ltd • Updated: 2025-09-16 20:41:53
-
8BusinessHighThe sector shows potential with increasing health awareness, but competition is high.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages, indicating weaker profitability.
-
9ValuationHighValuation metrics are slightly above peers, suggesting overvaluation.
-
6BalanceGoodModerate debt levels with limited liquidity raise concerns.
-
7GovernanceHighPromoter holding is decent, but there are some pledging issues.
-
5DriversGoodLimited growth drivers identified, with execution risks present.
-
1TechnicalsLowWeak market sentiment and low liquidity observed.
Final Score & Verdict
Score 48 / 100
• Risky
Emmessar Biotech and Nutrition Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 60/100